Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience

BACKGROUND: To investigate the potential benefit of cytoreductive radiotherapy (cRT) in metastatic castration-resistant prostate cancer (mCRPC) patients receiving abiraterone. METHODS: From February 2014 to February 2019, 149 mCRPC patients treated with abiraterone were identified. Patients receivin...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Long, Wen, Zhang, Zitong, Mai, Lixin, Huang, Sijuan, Liu, Boji, Cao, Wufei, Wu, Jianhua, Zhou, Fangjian, Li, Yonghong, He, Liru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789459/
https://www.ncbi.nlm.nih.gov/pubmed/33407637
http://dx.doi.org/10.1186/s13014-020-01732-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789459/
https://www.ncbi.nlm.nih.gov/pubmed/33407637
http://dx.doi.org/10.1186/s13014-020-01732-y

Ejemplares similares